KR20030059173A - 프라바스타틴 락톤과 에피-프라바스타틴을 실질적으로함유하지 않는 프라바스타틴 나트륨, 및 이를 포함하는조성물 - Google Patents

프라바스타틴 락톤과 에피-프라바스타틴을 실질적으로함유하지 않는 프라바스타틴 나트륨, 및 이를 포함하는조성물 Download PDF

Info

Publication number
KR20030059173A
KR20030059173A KR10-2003-7004764A KR20037004764A KR20030059173A KR 20030059173 A KR20030059173 A KR 20030059173A KR 20037004764 A KR20037004764 A KR 20037004764A KR 20030059173 A KR20030059173 A KR 20030059173A
Authority
KR
South Korea
Prior art keywords
pravastatin
sodium
pravastatin sodium
salt
substantially pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR10-2003-7004764A
Other languages
English (en)
Korean (ko)
Inventor
케리빌모스
디크라조스
포각스일로나
스자보크사바
나진아바이에디트
Original Assignee
비오갈 기오기스제르갸르 알티.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20030059173(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 비오갈 기오기스제르갸르 알티. filed Critical 비오갈 기오기스제르갸르 알티.
Publication of KR20030059173A publication Critical patent/KR20030059173A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2003-7004764A 2000-10-05 2001-10-05 프라바스타틴 락톤과 에피-프라바스타틴을 실질적으로함유하지 않는 프라바스타틴 나트륨, 및 이를 포함하는조성물 Abandoned KR20030059173A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23827800P 2000-10-05 2000-10-05
US60/238,278 2000-10-05
PCT/US2001/031230 WO2002030415A1 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Publications (1)

Publication Number Publication Date
KR20030059173A true KR20030059173A (ko) 2003-07-07

Family

ID=22897222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7004764A Abandoned KR20030059173A (ko) 2000-10-05 2001-10-05 프라바스타틴 락톤과 에피-프라바스타틴을 실질적으로함유하지 않는 프라바스타틴 나트륨, 및 이를 포함하는조성물

Country Status (18)

Country Link
EP (1) EP1330245A4 (enExample)
JP (6) JP3737801B2 (enExample)
KR (1) KR20030059173A (enExample)
CN (1) CN1468098A (enExample)
AU (1) AU2002211462A1 (enExample)
CA (1) CA2422744A1 (enExample)
CZ (1) CZ20031166A3 (enExample)
HR (1) HRP20030347A2 (enExample)
HU (1) HUP0400913A2 (enExample)
IL (1) IL155194A0 (enExample)
IS (1) IS6766A (enExample)
MX (1) MXPA03002963A (enExample)
NO (1) NO20031532L (enExample)
NZ (1) NZ525631A (enExample)
PL (1) PL361230A1 (enExample)
SK (1) SK5232003A3 (enExample)
WO (1) WO2002030415A1 (enExample)
ZA (1) ZA200302313B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1798214A3 (en) * 1999-11-30 2007-08-01 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for recovering statin compounds from a fermentation broth
EP1481674B1 (en) * 1999-11-30 2008-01-02 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
AU1804601A (en) * 1999-11-30 2001-06-12 Biogal Gyogyszergyar Rt Process for recovering statin compounds from a fermentation broth
KR20020062340A (ko) 1999-12-14 2002-07-25 비오갈 기오기스제르갸르 알티. 신규 형태의 프라바스타틴 나트륨
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TWI319707B (en) * 2003-11-24 2010-01-21 Method of purifying pravastatin
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
ES2254028B1 (es) * 2004-11-29 2007-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de pravastatina sodica purificada.
KR20070099034A (ko) * 2005-02-25 2007-10-08 테바 파마슈티컬 인더스트리즈 리미티드 타달라필의 정제 방법
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN114031496B (zh) * 2021-11-30 2024-09-27 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378441A (en) * 1963-10-17 1968-04-16 S B Penick & Company Tetraene antibiotic purification
JPS5221594B2 (enExample) * 1973-09-29 1977-06-11
CH624956A5 (de) * 1975-02-07 1981-08-31 Glaxo Operations Ltd Verfahren zur entfernung von verunreinigungen aus clavulansaeure.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
JPS5890509A (ja) * 1981-11-25 1983-05-30 Sankyo Co Ltd 高コレステロ−ル血症治療用組成物
JPH01190661A (ja) * 1988-01-22 1989-07-31 Konishi Kagaku Kogyo Kk ４，４′−ジヒドロキシジフエニルスルホンの精製法
JP2739328B2 (ja) * 1988-09-14 1998-04-15 日本ケミファ株式会社 ベンズイミダゾール化合物の精製方法
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
JPH06256278A (ja) * 1993-03-03 1994-09-13 Nissan Chem Ind Ltd 光学活性α−カルバモイルアルカン酸誘導体およびその製法
CA2126365C (en) * 1993-07-06 1999-08-24 Steven W. Felman Recovery of citric acid from impure process streams by addition of strong acids and salts thereof
AU677890B2 (en) * 1994-03-31 1997-05-08 Danisco Cultor America, Inc. Process for natamycin recovery
JPH11501218A (ja) * 1995-08-03 1999-02-02 ギスト ブロカデス ベスローテン フェンノートシャップ アシル化された化合物の脱アシル化の選択的方法
JPH09124655A (ja) * 1995-11-01 1997-05-13 Sankyo Co Ltd 新規スクアレンシンターゼ阻害活性化合物
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
JP2000229855A (ja) * 1998-12-07 2000-08-22 Satoshi Takebe プラバスタチンナトリウム錠
ATE294771T1 (de) * 1999-02-03 2005-05-15 Inst Drug Res Ltd Mikrobielles verfahren zur herstellung von pravastatin
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
AU1804601A (en) * 1999-11-30 2001-06-12 Biogal Gyogyszergyar Rt Process for recovering statin compounds from a fermentation broth
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Also Published As

Publication number Publication date
AU2002211462A1 (en) 2002-04-22
IS6766A (is) 2003-04-01
JP3737801B2 (ja) 2006-01-25
NO20031532D0 (no) 2003-04-04
JP2006036781A (ja) 2006-02-09
EP1330245A1 (en) 2003-07-30
EP1330245A4 (en) 2004-10-20
IL155194A0 (en) 2003-11-23
HRP20030347A2 (en) 2005-04-30
JP2004510817A (ja) 2004-04-08
NO20031532L (no) 2003-04-04
CZ20031166A3 (cs) 2004-04-14
NZ525631A (en) 2005-05-27
JP2009268479A (ja) 2009-11-19
SK5232003A3 (en) 2004-06-08
CN1468098A (zh) 2004-01-14
WO2002030415A9 (en) 2002-10-31
PL361230A1 (en) 2004-10-04
JP2015212300A (ja) 2015-11-26
ZA200302313B (en) 2004-03-25
MXPA03002963A (es) 2005-01-25
HUP0400913A2 (en) 2006-11-28
WO2002030415A1 (en) 2002-04-18
JP2013128486A (ja) 2013-07-04
JP2005013238A (ja) 2005-01-20
CA2422744A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
JP2015212300A (ja) プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウムの製造方法
US6689590B2 (en) Process for recovering statin compounds from a fermentation broth
US6936731B2 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US20050215636A1 (en) Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
US20080300305A1 (en) Method of purifying pravastatin
CA2581031A1 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
EP1481674B1 (en) Process for recovering statin compounds from a fermentation broth
AU2013204129B2 (en) Crystal Form of Quinoline Compound and Process for its Production
HK1071522A (en) Process for recovering statin compounds from a fermentation broth
EP1798214A1 (en) Process for recovering statin compounds from a fermentation broth
HK1053642A (en) Method of purifying pravastatin or its pharmacologically acceptable salt

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030403

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20030611

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050628

Patent event code: PE09021S01D

PC1902 Submission of document of abandonment before decision of registration
SUBM Surrender of laid-open application requested